CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.196
NA - Nord America 14.727
EU - Europa 6.970
SA - Sud America 1.647
Continente sconosciuto - Info sul continente non disponibili 399
AF - Africa 220
OC - Oceania 44
Totale 39.203
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.265
CN - Cina 5.275
SG - Singapore 4.043
IT - Italia 2.330
HK - Hong Kong 1.787
GB - Regno Unito 1.372
BR - Brasile 1.288
KR - Corea 979
VN - Vietnam 959
BD - Bangladesh 919
FI - Finlandia 897
RU - Federazione Russa 389
DE - Germania 388
SE - Svezia 346
FR - Francia 339
IN - India 255
ID - Indonesia 253
NL - Olanda 215
CA - Canada 200
JP - Giappone 130
LT - Lituania 129
AR - Argentina 128
MX - Messico 118
UA - Ucraina 113
TR - Turchia 112
IQ - Iraq 102
IE - Irlanda 69
AT - Austria 64
EC - Ecuador 56
ZA - Sudafrica 55
AE - Emirati Arabi Uniti 53
PK - Pakistan 48
BG - Bulgaria 46
ES - Italia 45
CO - Colombia 44
AU - Australia 42
CZ - Repubblica Ceca 39
PL - Polonia 37
VE - Venezuela 35
CL - Cile 29
JM - Giamaica 29
SA - Arabia Saudita 29
UZ - Uzbekistan 28
CR - Costa Rica 26
KE - Kenya 26
TN - Tunisia 26
EG - Egitto 25
MA - Marocco 25
PY - Paraguay 25
MY - Malesia 24
TW - Taiwan 24
TH - Thailandia 20
NP - Nepal 19
PH - Filippine 19
DZ - Algeria 17
PT - Portogallo 17
CH - Svizzera 16
UY - Uruguay 16
PE - Perù 15
GT - Guatemala 14
HN - Honduras 14
IL - Israele 14
JO - Giordania 14
RO - Romania 14
BE - Belgio 13
OM - Oman 13
TT - Trinidad e Tobago 13
BY - Bielorussia 11
NI - Nicaragua 11
BO - Bolivia 10
DO - Repubblica Dominicana 10
GR - Grecia 10
HU - Ungheria 10
DK - Danimarca 9
KZ - Kazakistan 9
AZ - Azerbaigian 8
AL - Albania 7
HR - Croazia 7
PS - Palestinian Territory 7
SV - El Salvador 7
SY - Repubblica araba siriana 7
AO - Angola 6
EU - Europa 6
KG - Kirghizistan 6
QA - Qatar 6
SC - Seychelles 6
SK - Slovacchia (Repubblica Slovacca) 6
BB - Barbados 5
IR - Iran 5
MD - Moldavia 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
LB - Libano 4
LV - Lettonia 4
MN - Mongolia 4
NO - Norvegia 4
UG - Uganda 4
BH - Bahrain 3
BN - Brunei Darussalam 3
Totale 38.741
Salva come PNG Salva come JPEG
Città #
Hefei 3.388
Singapore 2.433
Santa Clara 1.917
Ashburn 1.839
Hong Kong 1.688
San Jose 1.323
Seoul 972
Council Bluffs 890
Helsinki 816
London 697
Fairfield 512
The Dalles 441
Los Angeles 390
Southend 381
Milan 335
Ho Chi Minh City 332
Beijing 327
New York 324
Houston 286
Woodbridge 260
Chicago 258
Seattle 231
Lauterbourg 221
Hanoi 208
Buffalo 201
Kent 197
Chandler 195
Nyköping 191
Rome 183
Dallas 181
Jakarta 180
Wilmington 178
Cambridge 160
Ann Arbor 158
Boardman 141
Jacksonville 134
São Paulo 130
Moscow 115
Dearborn 114
Munich 107
Salt Lake City 96
Shanghai 96
Columbus 93
Amsterdam 92
Redondo Beach 81
San Diego 75
Modena 74
Bologna 73
Phoenix 71
Frankfurt am Main 69
Dublin 68
Atlanta 63
Nuremberg 63
Tokyo 63
Mexico City 59
Reggio Emilia 57
Tampa 57
Elk Grove Village 55
Da Nang 53
Brooklyn 52
Delhi 51
Washington 51
North Bergen 47
Boston 46
Guangzhou 44
Hillsboro 42
Miami 41
Naples 41
Princeton 41
Turin 41
Rio de Janeiro 40
Sofia 40
Toronto 40
Baghdad 38
Miano 38
Belo Horizonte 36
Florence 36
Izmir 35
Orem 35
Charlotte 34
Montreal 32
Kilburn 30
Lappeenranta 30
Brasília 29
Eugene 29
Mumbai 29
San Francisco 29
Palermo 28
Philadelphia 27
Shenzhen 27
Johannesburg 26
Vienna 26
Warsaw 26
Curitiba 25
Detroit 25
Haiphong 25
Sterling 25
Bari 24
Biên Hòa 24
Des Moines 24
Totale 25.801
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 447
Mucorales-specific T cells in patients with hematologic malignancies 382
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients 361
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 355
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 333
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 326
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 325
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 324
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 306
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 291
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 286
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 271
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 271
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 270
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 269
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group 268
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 265
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 265
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 257
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation 248
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 243
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 235
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 232
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 228
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 227
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 226
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 224
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 222
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 220
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 218
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 216
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 210
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 205
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 204
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 204
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 203
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 203
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 202
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 199
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 196
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 194
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 194
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG 192
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients 192
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 192
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 190
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 189
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 186
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 184
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 183
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 181
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 177
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey 169
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 169
Advanced mast cell disease: An Italian Hematological Multicenter experience 168
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 167
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 166
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 166
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 165
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial 163
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 161
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 161
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 160
Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression 160
Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia 159
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 158
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 158
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 153
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 153
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 152
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 151
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 150
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial 149
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 148
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 148
Systemic antifungal treatment after posaconazole prophylaxis: Results from the SEIFEM 2010-C survey 147
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia 147
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination 147
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 147
FLAI induction regimen in elderly patients with acute myeloid leukemia 146
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 145
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 145
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 144
Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study 144
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 143
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 143
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 141
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 140
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 140
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 139
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy 139
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease 139
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 138
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study 137
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 136
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax 135
Fungaemia in haematological malignancies: SEIFEM-2015 survey 134
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 134
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 133
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia 133
Totale 19.861
Salva come PNG Salva come JPEG
Categoria #
all - tutte 200.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 200.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022590 0 0 59 44 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/20259.165 218 117 96 624 1.549 1.063 390 347 1.016 886 1.539 1.320
2025/202620.269 1.801 1.492 2.461 2.005 1.240 1.267 2.716 854 1.550 1.661 1.641 1.581
2026/20272.800 854 1.399 547 0 0 0 0 0 0 0 0 0
Totale 39.203